Wu, Y., Mok, T. S. K., Han, J., Ahn, M., Delmonte, A., Ramalingam, S. S., Kim, S., Shepherd, F. A., Laskin, J., He, Y., Akamatsu, H., Theelen, W. S. M. E., Su, W., John, T., Sebastian, M., Mann, H., Miranda, M., Laus, G., Rukazenkov, Y., & Papadimitrakopoulou, V. (n.d.). 475OOverall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI). Annals of oncology, 30, . http://access.bl.uk/ark:/81055/vdc_100098038520.0x000038